Mirum Q2 net product sales $176M, raises FY guidance to $680-700M; volixibat NDA delayed to H1 2027

Mirum Pharmaceuticals, Inc.

Q2 2026 net product sales $176.2M, up 38% YoY; LIVMARLI sales $128.7M (+46% YoY), Bile Acid Medicines $47.5M (+20% YoY).
Full-year 2026 net product sales guidance raised to $680-700M from prior range.
Volixibat granted Breakthrough Therapy and Orphan Drug Designations for PSC; pre-NDA meeting recommended Phase 3 study, NDA submission now targeted H1 2027.
Issued $690M of 0.00% convertible senior notes due 2032; settled $237.2M of 4.00% notes due 2029.
Cash and investments $561.3M as of June 30, 2026; zilurgisertib PDUFA date Sept 26, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.